Core Insights - Medtronic plc (MDT) presented the two-year results of the SMART trial, the largest international head-to-head trial comparing TAVR options for patients with aortic stenosis and small aortic annulus at the CRT 2025 conference [1][2][6] Company Performance - The SMART trial results indicate that the Evolut TAVR valve outperforms the SAPIEN TAVR valve, showing significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less hemodynamic structural valve dysfunction [5][6] - Following the news, MDT's share price increased by 0.01% to $94.51, reflecting positive market sentiment towards the company's Structural Heart business [3] - Medtronic has a market capitalization of $121.20 billion and has delivered an average earnings surprise of 1.75% over the last four quarters [4] Industry Outlook - The global transcatheter aortic valve replacement market is projected to grow at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2030, driven by the rising prevalence of aortic stenosis, increasing preference for minimally invasive procedures, and a growing geriatric population [7]